Literature DB >> 18256922

GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?

S Kol1, I Solt.   

Abstract

PURPOSE: An update on the subject of ovarian hyperstimulation syndrome (OHSS) prevention with GnRH agonist ovulation trigger.
METHODS: Review of pertinent English language studies published during the past 4 years.
RESULTS: Randomized prospective studies support the notion that agonist trigger completely eliminates OHSS. Conflicting results regarding on going pregnancy rate probably reflect different approaches to luteal phase support. Embryos obtained and frozen after agonist trigger yield good clinical outcome in subsequent thaw cycles.
CONCLUSIONS: The notion that agonist trigger can eliminate OHSS is strongly supported by randomized controlled trials. Further research is needed to assess optimal luteal support post agonist trigger.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18256922      PMCID: PMC2582114          DOI: 10.1007/s10815-008-9198-1

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  13 in total

1.  A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.

Authors:  E M Kolibianakis; A Schultze-Mosgau; A Schroer; A van Steirteghem; P Devroey; K Diedrich; G Griesinger
Journal:  Hum Reprod       Date:  2005-06-24       Impact factor: 6.918

2.  Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.

Authors:  Rachel Babayof; Ehud J Margalioth; Mahmoud Huleihel; Alaa Amash; Edit Zylber-Haran; Michael Gal; Baruch Brooks; Tzvia Mimoni; Talia Eldar-Geva
Journal:  Hum Reprod       Date:  2006-01-26       Impact factor: 6.918

3.  Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.

Authors:  Evangelos G Papanikolaou; Cristina Pozzobon; Efstratios M Kolibianakis; Michel Camus; Herman Tournaye; Human M Fatemi; Andre Van Steirteghem; Paul Devroey
Journal:  Fertil Steril       Date:  2006-01       Impact factor: 7.329

4.  GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.

Authors:  G Griesinger; K Diedrich; P Devroey; E M Kolibianakis
Journal:  Hum Reprod Update       Date:  2005-10-27       Impact factor: 15.610

5.  GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.

Authors:  P Humaidan; H Ejdrup Bredkjaer; L Bungum; M Bungum; M L Grøndahl; L Westergaard; C Yding Andersen
Journal:  Hum Reprod       Date:  2005-03-10       Impact factor: 6.918

6.  Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.

Authors:  G Griesinger; S von Otte; A Schroer; A K Ludwig; K Diedrich; S Al-Hasani; A Schultze-Mosgau
Journal:  Hum Reprod       Date:  2007-02-15       Impact factor: 6.918

7.  Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period.

Authors:  A Pellicer; D Valbuena; F Cano; J Remohí; C Simón
Journal:  Fertil Steril       Date:  1996-06       Impact factor: 7.329

8.  Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.

Authors:  Georg Griesinger; E M Kolibianakis; E G Papanikolaou; K Diedrich; A Van Steirteghem; P Devroey; Helle Ejdrup Bredkjaer; Peter Humaidan
Journal:  Fertil Steril       Date:  2007-04-23       Impact factor: 7.329

9.  The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.

Authors:  Lawrence Engmann; Andrea DiLuigi; David Schmidt; John Nulsen; Donald Maier; Claudio Benadiva
Journal:  Fertil Steril       Date:  2007-04-26       Impact factor: 7.329

10.  Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients.

Authors:  C Simón; F Cano; D Valbuena; J Remohí; A Pellicer
Journal:  Hum Reprod       Date:  1995-09       Impact factor: 6.918

View more
  5 in total

Review 1.  Fertility considerations in young women with hematological malignancies.

Authors:  Pascale Jadoul; S Samuel Kim
Journal:  J Assist Reprod Genet       Date:  2012-05-22       Impact factor: 3.412

Review 2.  Clinical cases in oncofertility.

Authors:  Laxmi A Kondapalli; Fanzhen Hong; Clarisa R Gracia
Journal:  Cancer Treat Res       Date:  2010

Review 3.  Current approach to fertility preservation by embryo cryopreservation.

Authors:  Giuliano Bedoschi; Kutluk Oktay
Journal:  Fertil Steril       Date:  2013-03-25       Impact factor: 7.329

4.  Comparing the effect of gonadotropin-releasing hormone agonist and human chorionic gonadotropin on final oocytes for ovulation triggering among infertile women undergoing intrauterine insemination: An RCT.

Authors:  Robabeh Taheripanah; Marzieh Zamaniyan; Atefeh Moridi; Anahita Taheripanah; Narges Malih
Journal:  Int J Reprod Biomed       Date:  2017-06

Review 5.  Volume expanders for the prevention of ovarian hyperstimulation syndrome.

Authors:  Mohamed A Youssef; Selma Mourad
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.